Inventiva announces temporary trading halt of its ordinary shares on Euronext Paris
Daix (France), July 10, 2020 – INVENTIVA S.A. (Euronext Paris: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of
oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (“NASH”), mucopolysaccharidoses (“MPS”) and other diseases with significant unmet medical need,
announced today that trading of its ordinary shares on the regulated market of Euronext in Paris (“Euronext Paris”) will be temporarily halted, at the Company’s request, from the opening of
the market at 9:00 AM CET. This trading halt takes place in the context of the initial public offering of the Company on the Nasdaq Global Market, in order to allow for the confirmation of
allocations to investors and for the commencement of trading of the Company’s American Depositary Shares (“ADSs”) on the Nasdaq Global Market.
This suspension will be effective until a new communication is released by the Company. Trading on the regulated market of Euronext Paris is expected to resume today, July 10, 2020, at approximately 3:30 pm (CET), which is the earliest time ADSs are expected to begin trading on the Nasdaq Global Market (09:30 am (EST)) under the ticker symbol “IVA”.
Inventiva is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of NASH, MPS and other diseases with significant unmet medical need.
Leveraging its expertise and experience in the domain of compounds targeting nuclear receptors, transcription factors and epigenetic modulation, Inventiva is currently advancing two clinical candidates, as well as a deep pipeline of earlier stage programs.
Lanifibranor, its lead product candidate, is being developed for the treatment of patients with NASH, a common and progressive chronic liver disease for which there are currently no approved therapies. Inventiva recently announced positive topline data from its Phase IIb clinical trial evaluating lanifibranor for the treatment of patients with NASH.
Inventiva is also developing odiparcil, a second clinical stage asset, for the treatment of patients with subtypes of MPS, a group of rare genetic disorders. A Phase I/II clinical trial in children with MPS VI is currently under preparation following the release of positive results of the Phase IIa clinical trial in adult MPS VI patients at the end of 2019.